Elpiscience Biopharma, Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Shanghai China (2017)

Organization Overview

First Clinical Trial
2019
NCT04009460
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Elpiscience Biopharma Australia Pty. Ltd. | Elpiscience Biopharma, Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

es101 (2 trials)

Drugs in Phase 1 Trials (5)

es002023 (1 trial)

es009 (1 trial)

es014 (1 trial)

es102 (2 trials)

triprizumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 6